Brazilian magnet metals lift Axel
Axel REE has surged on a hit of up to 2.8% total rare earth oxides from its Caladao project in Brazil’s Lithium Valley.
News
America’s mega lithium resource
Lithium Americas has unveiled a massive 85-year mine life for the Thacker Pass project, with a host of ASX juniors in the neighbourhood.
AI buzz comes to minerals exploration
An AI-powered explorer backed by Bill Gates and Jeff Bezos is bringing tech money to mining. What does KoBold’s US$537 million raising mean?
Morningstar’s ASX sector and stock tips
Telcos and energy are strong, while retail and healthcare show promise. So says Morningstar as it seeks value, breaking down all 11 sectors on the ASX.
BHP backs junior Firetail for major copper find
BHP has given an ASX-listed explorer a shot in the arm, backing Firetail Resources to find a world-class copper project in Peru.
Tony’s Takeaway: 2025 watchlist
Host Tony Locantro of Alto Capital shares his top stocks to watch for 2025 in this episode of Tony’s Takeaway.
Road to 2025: FBM
In this episode, Sarah Hughan takes a look at lithium explorer Future Battery Minerals and what’s in sight in 2025.
Road to 2025: Hipages
In this episode, host Sarah Hughan recaps the past 12 months for Hipages and discusses what it has coming up in 2025.
Percheron speaks up after drug trial fail
Percheron’s board has written a letter to shareholders following failure of its phase 2b trial of lead candidate avicursen into non-ambulant boys with Duchenne muscular dystrophy.
VRX bags green tick for sand mine
Just ministerial approval sits between VRX and a final pass for its Arrowsmith North silica sand mine in WA.
Investing giants back gold
Gold prices could rise to fresh highs again in 2025, with a big dog investor saying US$3100/oz could be on the cards.
ASX slips; Star falls on cash crisis
The ASX has slipped on Thursday as energy stocks drag. Meanwhile Wall Street has stalled and Star Entertainment Group has a cash burn crisis.
2025 could be a ‘landmark’ year for capital investment
The stage is set for 2025 to be a transformative year for global capital investment. For investors, this presents a wealth of opportunities.
Canaccord eyes a couple of goldies
Canaccord raises Emerald’s target, and it still rates Bellvue a solid speculative buy despite a slight downgrade.
Road to 2025: BlinkLab
In this episode, host Sarah Hughan recaps the past 12 months for BB1 and discusses what it has coming up in 2025.
ASX jumps on inflation shock
The ASX popped on Wednesday as inflation rose, miners ripped, and Energy Transition Minerals rocketed on Trump’s Greenland talk.
ASX to dive after Wall Street falls, AI worries rise
The Nasdaq tumbled over 2pc overnight as concerns grow over big tech’s ability to turn AI investments into immediate profits.
Rise and Shine: Everything you need to know before the ASX opens – August 26, 2024
Good morning, and Happy Monday! Here’s everything you need to know before the ASX opens today.
ASX Small Caps Lunch Wrap
Local markets have fallen this morning, after disappointing earnings and inflation numbers really dampened the mood.
ASX Small Caps Lunch Wrap
Local markets dip on resources sell down as China goes on holiday.
ASX to rise as Tesla’s vagueness and China confuse
The ASX will open higher today despite mixed signals from China’s economy and Tesla’s vague announcements about its new ‘robotaxi’.
Scandium pop, bonanza gold and Greenland ‘Trump Bump’
Scandium resource upgrade sends Australian Mines flying, Meeka Metals up on gold hit, Trump’s Greenland obsession puts explorer in focus.
Avita falls 19% on earnings downgrade
Dual-listed regenerative medicine company Avita Medical has seen its share price slide ~19% today on a downgrade of its earnings guidance.
ASX up on CPI surprise; GTM pops on Trump talk
The ASX keeps charging on Wednesday. Meanwhile Wall Street slips on strong US data and Energy Transition Minerals pops on Trump’s Greenland chatter.
Biotech body prepares to bat for the sector
Ausbiotech hopes to score some quick runs with a pre-budget submission on ways to fix the sector’s “stubborn issues”.
December’s ASX health sector winners and losers
The S&P/ASX 200 Health Care (ASX:XHJ) Index fell 1.85% in December and rose 7.51% in 2024 to place seventh out of the 11 S&P/ASX 200 sectors.
ASX rises as 4DMedical gets US FDA nod
The ASX 200 edged up on tech gains on Tuesday, while miners slipped, Barrick eyed Mali shutdown, Bitcoin bounced and 4DMedical scored an FDA win.
Health Check: Opyl enters JV
Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another licensing deal.
Kalamazoo, Boab amongst top resource gainers
Kalamazoo Resources led materials sector gainers this morning as the release of drill assays from its Mallina West gold project draws closer.
Break it Down: Dimerix inks major Japanese partnership
Fraser Palamara details Dimerix’s deal with Japanese pharmaceutical company FUSO to fight a deadly kidney disease.
Stocks, Bitcoin roar; Capricorn hits gold record
ASX climbs on Tuesday, Bitcoin surges past US$102k on Trump’s crypto push and Capricorn hits a gold record.
Small cap stocks to watch in 2025
The ASX’s strong performance last year means investors need to dig deeper for value – and the small to mid-cap sector arguably presents the best opportunities.
A cancer-battling biotech with a fighting chance
Cell therapies have suffered from hyped-up expectations, clinical setbacks and high development/manufacturing costs. But maybe, just maybe Arovella has a shot at the title.
Archer, Brainchip led ASX tech in December
ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip cashed in on major contracts.
Health Kick Podcast: Neurizon gears up for 2025
Neurizon Therapeutics recently received EMA orphan designation for NUZ-001 to treat ALS and filed an FDA IND application to begin a phase 2/3 HEALEY ALS trial, pending FDA review.
Santa didn’t rally but these stocks fared okay in December
The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again. But… it wasn’t ALL bad, as these 50 stocks proved.
ASX November Health Winners
The ASX 200 Health Care Index rose 2.89% in November and is up 9.54%. ‘Momentum is starting to return,’ says Morgans healthcare analyst Scott Power.
Iron ore slump drags ASX, gold stocks fall
The ASX ended Monday flattish, while uranium miners rose after Cameco halted production. Also… news just in – Trudeau looks set to quit.
Summit soars on acquisition of Brazilian play
Summit Minerals led resource gainers on Monday after signing a deal to acquire the Mundo Novo niobium and rare earths project in central Brazil.
ASX keeps rolling as Nasdaq rebounds
ASX lifts on Wall Street bounce, energy stocks rise and Insignia jumps on takeover bid.
Gold stocking stuffers
Stockhead has filled your stocking with several ASX gold juniors that remain undervalued despite record gold prices.
Morgans’ ASX health picks for 2025
Morgans healthcare and life sciences experts Iain Wilkie and Scott Power give Stockhead readers their top picks for 2025.
Gas plays to watch in 2025
These ASX-listed gas companies have pending news flow of significance coming in 2025.
Analyst spots two top ASX stocks for growth
Morningstar picks ResMed and PWR as top ASX long-term plays, with ResMed eyeing sleep market domination.
How major commodities fared in 2024
Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a tumultuous 2024.
Economics for BCM’s ‘unique’ REE project coming soon
Brazilian Critical Minerals is looking forward to a big 2025 in which the market sees the value of its Ema rare earths project.
New rules force ASX firms to reveal climate plan
Aussie companies must report climate risks from 2025, giving investors more transparency on what’s coming.
Gold already hitting high notes in 2025
Gold prices rose ~1.5% on Thursday and Friday, following on from a ~26% annual gain, the metal’s ninth best in 50 years.
Uranium surges on ASX as Cameco halts output
The ASX rose on Friday on oil and uranium supply issues. Meanwhile the Aussie dollar slipped as gold and real estate climbed.
Elevate amongst uranium plays on the rise
Elevate Uranium, Bannerman Energy and Lotus Resources have made some of the biggest gains amongst the uranium companies rising today.
ASX rises, Paladin and Boss Energy soar
The ASX is edging up at lunch on Friday despite a Wall Street slump. Energy stocks have surged, the Aussie dollar has dipped and RBA rate cuts are at risk.
Uranium players rise on Kazakh woes
ASX uranium plays are rising amid hopes a Kazakh mine delay will lead to higher prices, plus Jervois and Fortescue.
December’s top 50 resources stocks
Aldoro led resources stock gains in December on strong niobium sampling results at its Kameelburg project in Namibia.
Bullish crypto eyes turn to Trump’s inauguration
December was a topsy turvy month for crypto, but growing stablecoin reserves could hint at a fresh rally as Trump’s inauguration approaches.
Famed local drug developer launches new biotech fund
The co-developer of one of only a few US-approved, locally-developed drugs, Professor Andrew Wilks has created a new fund to sniff out more winners.
ASX rebounds as Brainchip soars
Aussie shares moved up on Thursday. Energy stocks led, Lendlease dipped, Brainchip soared, and the AUD hit a two-year low.
Biotech shares soared in ’24
New data shows the 40 key ASX biotechs gained an average 50% in 2024 – but not everyone was a winner.
Azure’s former MD joins junior Lycaon
Tony Rovira was at the reins when Azure’s world-class Azure deposit was taken over by Hancock and SQM in a $1.7bn deal.
ASX up, Tesla explodes in Vegas, AUD drops
The ASX is on the up on Thursday, while Lendlease sells UK unit, Brainchip rallies again, the Aussie dollar drops and home prices slip.
Some mining project names are pure comedy gold
Settling on a name for a mineral deposit isn’t quite as important as naming a child but it’s clear some choose to be more creative than others, writes Kristie Batten.
Expert outlooks for markets in 2025
Donald Trump’s re-election as US president adds to uncertainty for the year ahead, according to leading analysts who have given their forecasts for global markets in 2025.
ASX miners who joined the $500m club
Gold miners were the big movers as ten ASX resources companies cleared a $500m market cap to join our Monsters of Rock club.
ASX healthcare’s 2024 winners and losers
Morgans analyst Iain Wilkie said 2024 was “pretty patchy” for the ASX healthcare sector, which underperformed broader markets.
A decent year, but ASX fizzles out for 2024
The ASX slipped again on 2024’s final day. It was still the best year since 2021 for the local bourse, however.
Resources Top 5: Speeding tickets and no news moves ring in the new year
5EA Advanced Materials has fended off a speeding ticket, while gold and Greenland explorers are among the no-news movers.
Pro Medicus notches another US contract win
A fresh $15 million deal takes radiology house Pro Medicus’s US contract wins in 2024 to at least $580 million.
Top 100 resources stocks for 2024
Numerous small caps delivered significant returns despite a tough market cycle. Here’s a collection of the top winners and gainers for 2024.
How ASX bulks performed in 2024
The ASX’s big iron ore and coal stocks let down the local market in 2024, but there were a handful of bulk winners.
ASX slips but Brainchip up 68pc in 5 days
ASX 200 drops as Santa rally fades, but energy, gold and Brainchip shine.
Gold M&A again leads the headlines
Maximus Resources has received a 7c per share takeover offer from neighbour Astral in a move that could combine the companies and their resources in the region.
Stocks fall on US debt ceiling fears
ASX falls after Wall Street sell-off, with Nvidia, Microsoft sliding and Bitcoin tumbling as traders take profits.
Telix files for key US approval
Telix CEO Chris Behrenbruch has been awarded a 68% base pay rise ahead of expected FDA approval of its kidney cancer diagnosis tool.
Gold M&A on the cards
With two juniors entering trading halts, more gold M&A could be coming in 2024. With prices near record highs, 2025 looks even wilder.
Felix sets ambitious antimony strategy
Felix Gold has laid its antimony ambitions bare, targeting 2025 restart of historic Scrafford mine in Alaska after this year’s price spike.
More small cap gems set to shine in 2025
After a stellar 2024 for recovering small to mid caps sector, our experts scour the sector for more overlooked nuggets.
Small caps poised to star in 2025
There are no dead-certs in small-cap investing, but here are some plays that just might rise and shine in 2025.
Bell Potter’s 2025 mining stocks to watch
Gold benefits from rate cuts, while copper shows long-term promise, with Bell Potter backing both for 2025.
2024’s top ASX gas performers
The gas market in 2024 offered both challenges and opportunities, here are the companies that threaded the needle and performed well.
Legally, share ownership may not be what you think
Investors should ask questions about custodial-based share arrangements by which they do not have legal ownership.
ASX up, Appen and Novonix race ahead
The ASX rallied on commodities boost on December 27. BrainChip and DroneShield led, while 2025 volatility looms with key risks.
Original URL: https://www.news.com.au/finance/business/stockhead/news/page/2